CRISPR Therapeutics
CRSP
174 hedge funds and large institutions have $1.09B invested in CRISPR Therapeutics in 2018 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 30 closing their positions.
133% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 30
63% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 32
29% more funds holding
Funds holding: 135 → 174 (+39)
27% more capital invested
Capital invested by funds: $855M → $1.09B (+$232M)
0.64% less ownership
Funds ownership: 39.84% → 39.2% (-0.64%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
66% less call options, than puts
Call options by funds: $29.7M | Put options by funds: $86.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$36M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$22.5M |
| 3 |
O
OrbiMed
New York
|
+$22.3M |
| 4 |
Two Sigma Advisers
New York
|
+$19M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$79.4M |
| 2 |
VVM
Versant Venture Management
San Francisco,
California
|
-$56.8M |
| 3 |
A
Abingworth
London,
United Kingdom
|
-$37M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$21.8M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$10.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SWP
201
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$21K | -465 | Closed |
|
|
SFM
202
Signet Financial Management
Parsippany,
New Jersey
| – | -$10K | -210 | Closed |
|
|
KF
203
Krilogy Financial
St. Louis,
Missouri
| – | -$9K | -200 | Closed |
|
204
Acadian Asset Management
Boston,
Massachusetts
| – | -$5K | -111 | Closed |
|
CRSP Hedge Fund Activity: Q2 2018 in Review
174 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2018, worth a combined $1.09B — up 27% from $855M a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new CRSP positions and 30 closed out — a net gain of 40 holders — while 52 added to existing stakes and 32 trimmed.
The largest buyer was Federated Hermes, opening a new position worth an estimated $36M. The largest seller was NEA Management Company, cutting an estimated $79.4M.
- 174 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2018, up from 135 in Q1 2018.
- Funds reported $1.09B of CRISPR Therapeutics stock for Q2 2018, up 27% quarter-over-quarter.
- 70 funds opened new CRISPR Therapeutics positions in Q2 2018 and 30 closed out, a net change of +40 holders.
- The largest CRISPR Therapeutics buyer in Q2 2018 was Federated Hermes, an estimated $36M added.
- The largest CRISPR Therapeutics seller in Q2 2018 was NEA Management Company, an estimated $79.4M sold.
Based on aggregated 13F filings for Q2 2018.